Cyfuse Biomedical KK

Cyfuse Biomedical KK Current Liabilities

The Current Liabilities of Cyfuse Biomedical KK (4892.T) as of Nov 2, 2026 is 825.65 M JPY. In the previous year, Current Liabilities was 664.13 M JPY — a change of 24.32% (higher).

Current Liabilities

825.65 MJPY

YoY

24.32%

Last updated:

Current Liabilities of Cyfuse Biomedical KK is 2025 825.65 M JPY. Current Liabilities of Cyfuse Biomedical KK was 2024 664.13 M JPY. It decreases by 24.32% higher compared to the previous year.

The Cyfuse Biomedical KK Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2020
223.71 M JPY
Jan 1, 2021
482.71 M JPY
Jan 1, 2022
734.93 M JPY
Jan 1, 2023
668.74 M JPY
Jan 1, 2024
664.13 M JPY
Jan 1, 2025
825.65 M JPY
The Cyfuse Biomedical KK Current Liabilities history
YEARCurrent LiabilitiesYoY
825.65 MJPY+24.32%
664.13 MJPY-0.69%
668.74 MJPY-9.01%
734.93 MJPY+52.25%
482.71 MJPY+115.78%
223.71 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cyfuse Biomedical KK Stock analysis

What does Cyfuse Biomedical KK do? Cyfuse Biomedical KK develops and manufactures cell regenerative systems, focusing on regenerative medicine products and drug discovery support tools. The company sells three-dimensional cell stacking system equipment, which includes basic technology and apply technology for cell product development. Its primary customers are pharmaceutical companies seeking drug discovery support and institutions requiring regenerative medicine solutions. The firm generates revenue through the sale of equipment and contract research services for cell products in the regenerative medicine field. Cyfuse Biomedical KK's business model centers on developing and selling three-dimensional cell stacking systems, which are used as tools for drug discovery support. The company also provides contract research services for cell products, targeting pharmaceutical companies and research institutions. Revenue streams include equipment sales and contract research, with a focus on regenerative medicine applications and drug discovery support. The company's product portfolio includes three-dimensional cell stacking system equipment, which incorporates basic technology and apply technology for cell product development. These systems are sold to pharmaceutical companies and research institutions for use in regenerative medicine and drug discovery. The firm's revenue is derived from the sale of equipment and the provision of contract research services in the regenerative medicine sector. Cyfuse Biomedical KK is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cyfuse Biomedical KK stock

Current Liabilities of Cyfuse Biomedical KK is 825.65 M JPY in 2025.

Current Liabilities of Cyfuse Biomedical KK changed from 664.13 M JPY to 825.65 M JPY, representing a 24.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Cyfuse Biomedical KK since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Cyfuse Biomedical KK historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Cyfuse Biomedical KK

All Key Metrics — Cyfuse Biomedical KK